Cargando…
Therapeutic ROS and Immunity in Cancer—The TRIC-21 Meeting
The first Therapeutic ROS and Immunity in Cancer (TRIC) meeting was organized by the excellence research center ZIK plasmatis (with its previous Frontiers in Redox Biochemistry and Medicine (FiRBaM) and Young Professionals’ Workshop in Plasma Medicine (YPWPM) workshop series in Northern Germany) and...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471836/ https://www.ncbi.nlm.nih.gov/pubmed/34572777 http://dx.doi.org/10.3390/cancers13184549 |
_version_ | 1784574570285498368 |
---|---|
author | Bekeschus, Sander Emmert, Steffen Clemen, Ramona Boeckmann, Lars |
author_facet | Bekeschus, Sander Emmert, Steffen Clemen, Ramona Boeckmann, Lars |
author_sort | Bekeschus, Sander |
collection | PubMed |
description | The first Therapeutic ROS and Immunity in Cancer (TRIC) meeting was organized by the excellence research center ZIK plasmatis (with its previous Frontiers in Redox Biochemistry and Medicine (FiRBaM) and Young Professionals’ Workshop in Plasma Medicine (YPWPM) workshop series in Northern Germany) and the excellence research program ONKOTHER-H (Rostock/Greifswald, Germany). The meeting showcased cutting-edge research and liberated discussions on the application of therapeutic ROS and immunology in cancer treatment, primarily focusing on gas plasma technology. The 2-day hybrid meeting took place in Greifswald and online from 15–16 July 2021, facilitating a wide range of participants totaling 66 scientists from 12 countries and 5 continents. The meeting aimed at bringing together researchers from a variety of disciplines, including chemists, biochemists, biologists, engineers, immunologists, physicists, and physicians for interdisciplinary discussions on using therapeutic ROS and medical gas plasma technology in cancer therapy with the four main sessions: “Plasma, Cancer, Immunity”, “Plasma combination therapies”, “Plasma risk assessment and patients studies”, and “Plasma mechanisms and treated liquids in cancer”. This conference report outlines the abstracts of attending scientists submitted to this meeting. |
format | Online Article Text |
id | pubmed-8471836 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84718362021-09-28 Therapeutic ROS and Immunity in Cancer—The TRIC-21 Meeting Bekeschus, Sander Emmert, Steffen Clemen, Ramona Boeckmann, Lars Cancers (Basel) Conference Report The first Therapeutic ROS and Immunity in Cancer (TRIC) meeting was organized by the excellence research center ZIK plasmatis (with its previous Frontiers in Redox Biochemistry and Medicine (FiRBaM) and Young Professionals’ Workshop in Plasma Medicine (YPWPM) workshop series in Northern Germany) and the excellence research program ONKOTHER-H (Rostock/Greifswald, Germany). The meeting showcased cutting-edge research and liberated discussions on the application of therapeutic ROS and immunology in cancer treatment, primarily focusing on gas plasma technology. The 2-day hybrid meeting took place in Greifswald and online from 15–16 July 2021, facilitating a wide range of participants totaling 66 scientists from 12 countries and 5 continents. The meeting aimed at bringing together researchers from a variety of disciplines, including chemists, biochemists, biologists, engineers, immunologists, physicists, and physicians for interdisciplinary discussions on using therapeutic ROS and medical gas plasma technology in cancer therapy with the four main sessions: “Plasma, Cancer, Immunity”, “Plasma combination therapies”, “Plasma risk assessment and patients studies”, and “Plasma mechanisms and treated liquids in cancer”. This conference report outlines the abstracts of attending scientists submitted to this meeting. MDPI 2021-09-10 /pmc/articles/PMC8471836/ /pubmed/34572777 http://dx.doi.org/10.3390/cancers13184549 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Conference Report Bekeschus, Sander Emmert, Steffen Clemen, Ramona Boeckmann, Lars Therapeutic ROS and Immunity in Cancer—The TRIC-21 Meeting |
title | Therapeutic ROS and Immunity in Cancer—The TRIC-21 Meeting |
title_full | Therapeutic ROS and Immunity in Cancer—The TRIC-21 Meeting |
title_fullStr | Therapeutic ROS and Immunity in Cancer—The TRIC-21 Meeting |
title_full_unstemmed | Therapeutic ROS and Immunity in Cancer—The TRIC-21 Meeting |
title_short | Therapeutic ROS and Immunity in Cancer—The TRIC-21 Meeting |
title_sort | therapeutic ros and immunity in cancer—the tric-21 meeting |
topic | Conference Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471836/ https://www.ncbi.nlm.nih.gov/pubmed/34572777 http://dx.doi.org/10.3390/cancers13184549 |
work_keys_str_mv | AT bekeschussander therapeuticrosandimmunityincancerthetric21meeting AT emmertsteffen therapeuticrosandimmunityincancerthetric21meeting AT clemenramona therapeuticrosandimmunityincancerthetric21meeting AT boeckmannlars therapeuticrosandimmunityincancerthetric21meeting |